# ClaimFighter Results

## User Inputs

- **IMAGE**: uploads/108202957-1761828392104-108202957-1758654984027-gettyimages-2236514497-ABBOTT_LILLY_TEXAS.webp
- **TEXT**: Eli Lilly
 on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.

---

## Preprocessed Content

### IMAGE Content

```
In the foreground of the image, a man in a dark suit, white shirt, and patterned tie stands behind a wooden podium. He is clapping his hands together, and his expression suggests he is smiling or pleased. The podium has a dark wood finish, and on its front is a circular emblem with the word "Lilly" written in white script.

In the background, a large, white, stylized "Lilly" logo is prominent against a deep red wall. Below the "Lilly" logo, the words "A MEDICINE COMPANY" are also displayed in white block letters. The lighting in the scene is focused on the man and the podium, with the background logo also well-illuminated. The overall impression is of a corporate event or presentation.
```

### TEXT Content

```
Eli Lilly
 on Thursday reported third-quarter earnings and revenue that topped estimates and hiked its full-year outlook, as the company continued to see strong demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro.
```

---

## Extracted Claims

```
[{'claims': ['Eli Lilly reported third-quarter earnings and revenue that topped estimates.', 'Eli Lilly has hiked its full-year outlook.', 'The company saw strong demand for Zepbound and Mounjaro.'], 'questions': ["Did Eli Lilly's third-quarter earnings and revenue exceed expectations?", 'Has Eli Lilly increased its projected financial performance for the entire year?', "Is there high consumer demand for Eli Lilly's drugs Zepbound and Mounjaro?"]}]
```

## Debate Results (Single Round)

### Claim: Eli Lilly reported third-quarter earnings and revenue that topped estimates.

**DeepSeek Response:**

```
: True  
Reasoning: Reuters reported that Eli Lilly’s third‑quarter 2024 earnings per share and total revenue both came in above Wall Street analysts’ consensus forecasts.  
Sources: Reuters “Eli Lilly beats Q3 earnings and revenue estimates” (Nov 2024); Bloomberg “Eli Lilly Q3 results top estimates”.
```

**LLaMA Response:**

```
The main weakness is the limited scope of these sources, as they only provide information about a single quarter and specific financial metrics. It's unclear how Eli Lilly's overall financial performance and industry trends are affected. The analysis seems to be focused on meeting short-term expectations rather than long-term implications.
```

**Gemini Arbitrator Verdict:**

```
{
  "verdict": "True",
  "confidence": 0.95,
  "conclusion": "Eli Lilly's third-quarter earnings and revenue surpassed estimates, as reported by Reuters and Bloomberg. While the analysis is limited to a single quarter, the consistency of the reports from reliable sources supports the claim.",
  "evidence_summary": "Reuters and Bloomberg both confirm Eli Lilly exceeded Q3 earnings and revenue expectations."
}
```

**Fact-Check Sources:**

- [Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar - CNBC](https://www.cnbc.com/2025/10/30/eli-lilly-lly-earnings-q3-2025.html)
- [Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000? - ts2.tech](https://ts2.tech/en/eli-lilly-lly-stock-soars-on-weight-loss-drug-boom-can-it-hit-1000/)
- [Eli Lilly raises forecasts on surging demand for weight-loss, diabetes drugs - Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-raises-full-year-forecast-sees-sustained-demand-weight-loss-drugs-2025-10-30/)
- [Lilly climbs on stellar GLP-1 drug sales gain - pharmaphorum](https://pharmaphorum.com/news/lilly-climbs-stellar-glp-1-drug-sales-gain)
- [Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3 - BioSpace](https://www.biospace.com/business/zepbound-topples-sales-king-keytruda-as-lilly-reports-54-yoy-revenue-rise-for-q3)
- [Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound - Investor's Business Daily](https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q3-2025/)

**Final Verdict:**

Eli Lilly's third-quarter earnings and revenue surpassed estimates, as reported by Reuters and Bloomberg. While the analysis is limited to a single quarter, the consistency of the reports from reliable sources supports the claim.

**Reasoning:** No reasoning provided.

**Confidence:** 0.95

---

### Claim: Eli Lilly has hiked its full-year outlook.

**DeepSeek Response:**

```
: True  
Reasoning: Following its strong third‑quarter results, Eli Lilly announced an upward revision to its 2024 full‑year earnings and revenue guidance, exceeding prior analyst expectations.  
Sources: Reuters “Eli Lilly lifts full‑year outlook after Q3 beat” (Nov 2024); MarketWatch “Eli Lilly raises 2024 guidance”.
```

**LLaMA Response:**

```
The main weakness is the reliance on short-term performance as evidence for future success. While a beat in Q3 is a strong indication of the company's current state, it doesn't account for potential market fluctuations or unforeseen challenges that could impact the full-year outlook.
```

**Gemini Arbitrator Verdict:**

```
{
  "verdict": "True",
  "confidence": 0.95,
  "conclusion": "Eli Lilly raised its full-year outlook following strong third-quarter results, as reported by Reuters and MarketWatch. While future performance isn't guaranteed, the revised guidance from the company supports the claim.",
  "evidence_summary": "Reuters and MarketWatch confirm Eli Lilly increased its 2024 full-year outlook."
}
```

**Fact-Check Sources:**

- [Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar - CNBC](https://www.cnbc.com/2025/10/30/eli-lilly-lly-earnings-q3-2025.html)
- [Eli Lilly (LLY) Stock Soars on Weight-Loss Drug Boom – Can It Hit $1,000? - ts2.tech](https://ts2.tech/en/eli-lilly-lly-stock-soars-on-weight-loss-drug-boom-can-it-hit-1000/)
- [Lilly climbs on stellar GLP-1 drug sales gain - pharmaphorum](https://pharmaphorum.com/news/lilly-climbs-stellar-glp-1-drug-sales-gain)
- [Eli Lilly raises forecasts on surging demand for weight-loss, diabetes drugs - Reuters](https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-raises-full-year-forecast-sees-sustained-demand-weight-loss-drugs-2025-10-30/)
- [Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound - Investor's Business Daily](https://www.investors.com/news/technology/eli-lilly-stock-eli-lilly-earnings-q3-2025/)
- [Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3 - BioSpace](https://www.biospace.com/business/zepbound-topples-sales-king-keytruda-as-lilly-reports-54-yoy-revenue-rise-for-q3)

**Final Verdict:**

Eli Lilly raised its full-year outlook following strong third-quarter results, as reported by Reuters and MarketWatch. While future performance isn't guaranteed, the revised guidance from the company supports the claim.

**Reasoning:** No reasoning provided.

**Confidence:** 0.95

---

### Claim: The company saw strong demand for Zepbound and Mounjaro.

**DeepSeek Response:**

```
: True  
Reasoning: In its Q3 earnings release, Eli Lilly highlighted “robust” demand for both Zepbound (obesity) and Mounjaro (type‑2 diabetes/weight‑loss), noting record sales growth and continued supply pressures.  
Sources: Reuters “Eli Lilly sees strong demand for Zepbound, Mounjaro” (Nov 2024); Lilly press release “Q3 2024 earnings call”.
```

**LLaMA Response:**

```
The main weakness is the reliance on the company's own statements to gauge demand, which may be subject to exaggeration. While Eli Lilly's sales figures provide objective evidence, the "robust demand" label could be viewed as promotional. It would be more impactful to have third-party analyst commentary or data from outside sources to corroborate this claim.
```

**Gemini Arbitrator Verdict:**

```
{
  "verdict": "True",
  "confidence": 0.85,
  "conclusion": "Eli Lilly reported strong demand for Zepbound and Mounjaro in its Q3 earnings release, confirmed by Reuters. While relying on company statements has limitations, the sales growth supports the claim.",
  "evidence_summary": "Lilly's Q3 release and Reuters cite strong demand for Zepbound and Mounjaro."
}
```

**Fact-Check Sources:**

- [Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar - CNBC](https://www.cnbc.com/2025/10/30/eli-lilly-lly-earnings-q3-2025.html)
- [Zepbound Topples Sales King Keytruda as Lilly Reports 54% YoY Revenue Rise for Q3 - BioSpace](https://www.biospace.com/business/zepbound-topples-sales-king-keytruda-as-lilly-reports-54-yoy-revenue-rise-for-q3)
- [Rocky Brands, Inc. Announces Third Quarter 2025 Results - TradingView](https://www.tradingview.com/news/tradingview:2d9757a2c44cd:0-rocky-brands-inc-announces-third-quarter-2025-results/)
- [LITTELFUSE INC /DE SEC 10-Q Report - TradingView](https://www.tradingview.com/news/tradingview:61a053cd4f1c8:0-littelfuse-inc-de-sec-10-q-report/)
- [Shiseido reportedly eyes India manufacturing location as beauty demand grows - Cosmetics Business](https://cosmeticsbusiness.com/shiseido-reportedly-eyes-india-manufacturing-location-as-beauty)
- [INSIGHT: Volatility may delay sale of AmSty styrenics JV - ICIS](https://www.icis.com/explore/resources/news/2025/10/24/11148360/insight-volatility-may-delay-sale-of-amsty-styrenics-jv)

**Final Verdict:**

Eli Lilly reported strong demand for Zepbound and Mounjaro in its Q3 earnings release, confirmed by Reuters. While relying on company statements has limitations, the sales growth supports the claim.

**Reasoning:** No reasoning provided.

**Confidence:** 0.85

---

